Foscavir Side Effects

Generic Name: foscarnet

Note: This page contains information about the side effects of foscarnet. Some of the dosage forms included on this document may not apply to the brand name Foscavir.

Not all side effects for Foscavir may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to foscarnet: intravenous solution

In addition to its needed effects, some unwanted effects may be caused by foscarnet (the active ingredient contained in Foscavir). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking foscarnet, check with your doctor or nurse immediately:

More common
  • Increased or decreased frequency of urination or amount of urine
  • increased thirst
Less common
  • Chills
  • convulsions
  • fever
  • muscle twitching
  • pain at place of injection
  • pain or numbness in hands or feet
  • tingling sensation around the mouth
  • tremor
  • unusual tiredness and weakness
  • Sores or ulcers on the mouth or throat, penis, or vulva

Some of the side effects that can occur with foscarnet may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Abdominal or stomach pain
  • anxious feeling
  • confusion
  • dizziness
  • headache
  • loss of appetite
  • nausea and vomiting
  • unusual tiredness or weakness

For Healthcare Professionals

Applies to foscarnet: intravenous solution


Renal impairment is the major toxicity of foscarnet (the active ingredient contained in Foscavir) The most frequent adverse events reported during clinical trials included fever (65%), nausea (47%), anemia (33%), diarrhea (30%), abnormal renal function (27%), vomiting (26%), headache (26%), and seizures (10%). Adverse events classified as severe included death (14%), abnormal renal function (14%), bone marrow suppression (10%), anemia (9%), and seizures (7%).[Ref]


Renal side effects have included dose-related renal impairment, which is the major toxicity of foscarnet (the active ingredient contained in Foscavir) and has occurred in up to 33% of patients. Acute renal failure, serum creatinine elevations greater than or equal to 2.9 mg/dL, renal tubular acidosis, and renal calculi have also been reported.[Ref]

Renal adverse effects are due to acute tubular necrosis, possibly from deposition of foscarnet crystals in the renal tubules and capillaries. Renal failure as well as tubular dysfunction such as nephrogenic diabetes insipidus may result. The development of nephrotoxicity was most common during the third week of therapy in one study.

Nephrotoxicity is reversible in patients with previously adequate renal function. Hydration with 2.5 liters of normal saline per day beginning the day before foscarnet therapy has been shown to decrease the incidence of nephrotoxicity.[Ref]


Gastrointestinal side effects have included nausea (47%), vomiting (26%), diarrhea (30%), anorexia (5% or more), and abdominal pain (5% or more). Constipation, dysphagia, dyspepsia, rectal hemorrhage, dry mouth, melena, flatulence, ulcerative stomatitis, and pancreatitis have been reported in 1% to 5% of patients. An isolated case of uvula and esophageal ulceration has been reported.[Ref]


Hematologic side effects have included anemia (33%), neutropenia (17%), granulocytopenia (5% or more), and leukopenia (5% or more). Thrombocytopenia, platelet abnormalities, thrombosis, blood cell abnormalities, and lymphadenopathy have been reported in 1% to 5% of patients.[Ref]

Nervous system

Nervous system side effects have included headache (26%) and seizures (10%). Paresthesia, dizziness, involuntary muscle contractions, hypoesthesia, neuropathy, and grand mal seizures have been reported in greater than or equal to 5% of patients. Tremor, ataxia, dementia, stupor, generalized spasms, sensory disturbances, meningitis, aphasia, abnormal coordination, leg cramps, and EEG abnormalities have been reported in 1% to 5% of patients. Risk factors for foscarnet-related seizures include low neutrophil count, central nervous system disease, impaired renal function, and electrolyte and metabolic abnormalities.[Ref]


Metabolic disturbances have occurred in 15% to 40% of patients treated with foscarnet (the active ingredient contained in Foscavir) and include hypocalcemia, hypomagnesemia, hypokalemia, hyponatremia secondary to nephrogenic diabetes insipidus, and hypo- and hyperphosphatemia. More severe metabolic abnormalities have resulted in tremors, twitches, arrhythmias, parenthesis, and seizures. Dehydration, hypoproteinemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and increased amylase and creatinine phosphokinase have been reported in less than 1% of patients. Hypercalcemia has also been reported.[Ref]

Serum ionized calcium concentrations have been shown to decrease acutely in a dose-dependent manner following an infusion of foscarnet. Total calcium and phosphate levels were not significantly affected. Foscarnet is believed to complex with ionized calcium.[Ref]


Other side effects have included fever (65%), and fatigue, rigors, asthenia, malaise, pain, infection, and sepsis in greater than or equal to 5% of patients.[Ref]


Local side effects have included injection site pain and inflammation.[Ref]


Dermatologic side effects have included rash and increased sweating in greater than or equal to 5% of patients. Pruritus, skin ulceration, seborrhea, erythematous rash, maculopapular rash, and skin discoloration have been reported in 1% to 5% of patients. Erythema multiforme, toxic epidermal necrolysis, eosinophilic folliculitis, and Stevens-Johnson syndrome have been reported during postmarketing experience.[Ref]


Reversible cardiac dysfunction has been reported in one patient receiving foscarnet (the active ingredient contained in Foscavir) who experienced shortness of breath, increased heart rate, and pulmonary edema, which reoccurred upon rechallenge. Serum electrolytes were within normal limits. Ventricular arrhythmia and QT interval prolongation have been reported during postmarketing experience.[Ref]

Cardiovascular side effects have included hypertension, palpitations, ECG abnormalities, sinus tachycardia, first degree AV block, nonspecific ST-T segment changes, hypotension, flushing, cerebrovascular disorder in 1% to 5% of patients. Cardiac arrest, coma, and other cardiovascular complications have been reported in less than 1% of patients.[Ref]


Hepatic side effects have included abnormal hepatic function, abnormal A-G ratio, increased SGPT, and increased SGOT in 1% to 5% of patients. Increased gamma glutamyl transpeptidase has been reported during postmarketing experience.[Ref]


Musculoskeletal side effects have included arthralgia and myalgia in 1% to 5% of patients. Myopathy, myositis, muscle weakness, and rhabdomyolysis have been reported during postmarketing experience.[Ref]


Oncologic side effects have included lymphoma-like disorder and sarcoma in 1% to 5% of patients.[Ref]


Respiratory side effects have included coughing and dyspnea in greater than or equal to 5% of patients. Pneumonia, sinusitis, pharyngitis, rhinitis, respiratory disorders, respiratory insufficiency, pulmonary infiltration, stridor, pneumothorax, hemoptysis, and bronchospasm have been reported in 1% to 5% of patients.[Ref]


Psychiatric side effects have included confusion and anxiety in greater than or equal to 5% of patients. Insomnia, somnolence, nervousness, amnesia, agitation, aggressive reaction, and hallucination have been reported in 1% to 5% of patients.[Ref]


Ocular side effects have included eye abnormalities, eye pain, and conjunctivitis in 1% to 5% of patients.[Ref]


Genitourinary side effects have included albuminuria, dysuria, polyuria, urethral disorder, urinary retention, urinary tract infections, and nocturia in 1% to 5% of patients, and hematuria in less than 1% of patients. Local irritation and ulceration of penile epithelium in male patients and vulvovaginal ulceration in a female patient have also been reported.[Ref]

Penile ulcerations have been reported to occur after a median of 11 days of induction therapy and 30 days of maintenance therapy, and heal within six days of drug discontinuation. Ulceration has been reported more often in uncircumcised patients. Vulvar erosion may also occur but is less common. Penile ulceration is thought to result from local irritation by high concentrations of foscarnet in the urine. Good hygiene may help reduce irritation.[Ref]


Foscarnet accumulates in teeth and bones of growing animals. Tooth enamel development has been affected in rats receiving foscarnet (the active ingredient contained in Foscavir) [Ref]


1. Takami A, Mochizuki K, Ito S, et al. "Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation." Transplant Proc 39 (2007): 237-9

2. "Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.

3. SOCA Reseach Group, et al "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med 326 (1992): 213-20

4. Zanetta G, MauriceEstepa L, Mousson C, Justrabo E, Daudon M, Rifle G, Tanter Y "Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation." Transplantation 67 (1999): 1376-8

5. Farese RV Jr, Schambelan M, Hollander H, et al "Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis." Ann Intern Med 112 (1990): 955-6

6. Deray G, Le Hoang P, Soubrie C, et al "Foscarnet-induced acute renal failure and effectiveness of haemodialysis." Lancet 2 (1987): 216

7. Navarro JF, Quereda C, Quereda C, Gallego N, Antela A, Mora C, Ortuno J "Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy." Am J Kidney Dis 27 (1996): 431-4

8. MauriceEstepa L, Daudon M, Katlama C, Jouanneau C, Sazdovitch V, Lacour B, Beaufils H "Identification of crystals in kidneys of AIDS patients treated with foscarnet." Am J Kidney Dis 32 (1998): 392-400

9. Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87

10. Willocks L, Brettle R "Foscarnet and pancytopenia." J Antimicrob Chemother 29 (1992): 232

11. Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7

12. Seidel EA, Koenig S, Polis MA "A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet." AIDS 7 (1993): 941-5

13. Navarro JF, Quereda C, Moreno A, Quereda C "Renal tubular acidosis following treatment with foscarnet." AIDS 9 (1995): 1389-90

14. Palestine AG, Polis MA, De Smet MD, et al "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med 115 (1991): 665-73

15. Deray G, Katlama C, Dohin E "Prevention of foscarnet nephrotoxicity." Ann Intern Med 113 (1990): 332

16. Goldfarb DS, Coe FL "Foscarnet crystal deposition and renal failure." Am J Kidney Dis 32 (1998): 519-20

17. Izzedine H, Launay-Vacher V, Deray G "Antiviral drug-induced nephrotoxicity." Am J Kidney Dis 45 (2005): 804-17

18. Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29

19. Blanshard C "Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet." J Acquir Immune Defic Syndr 5 (1992): s25-8

20. Cacoub P, Deray G, Baumelou A, et al "Acute renal failure induced by foscarnet: 4 cases." Clin Nephrol 29 (1988): 315-8

21. Deray G, Martinez F, Katlama C, et al "Foscarnet nephrotoxicity: mechanism, incidence and prevention." Am J Nephrol 9 (1989): 316-21

22. Szczech LA "Hypertension and medication-related renal dysfunction in the HIV-infected patient." Semin Nephrol 21 (2001): 386-93

23. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95

24. Wald A "New therapies and prevention strategies for genital herpes." Clin Infect Dis 28 (1999): s4-13

25. Saint-Marc T, Fournier F, Touraine J-L, Marneff E "Uvula and oesophageal ulcerations with foscarnet." Lancet 340 (1992): 970-1

26. Roos TC, Albrecht H "Foscarnet-associated eosinophilic folliculitis in a patient with AIDS." J Am Acad Dermatol 44 (2001): 546-7

27. Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994): 869-72

28. Lor E, Liu YQ "Neurologic sequelae associated with foscarnet therapy." Ann Pharmacother 28 (1994): 1035-7

29. Conn J, Colman P, Brown G, Street A, Bate K "Nephrogenic diabetes insipidus associated with foscarnet - a case report." J Antimicrob Chemother 37 (1996): 1179-81

30. Jacobson MA, Gambertoglio JG, Aweeka FT, et al "Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism." J Clin Endocrinol Metab 72 (1991): 1130-5

31. Gearhart MO, Sorg TB "Foscarnet-induced severe hypomagnesemia and other electrolyte disorders." Ann Pharmacother 27 (1993): 285-9

32. Malin A, Miller RF "Foscarnet-induced hypokalaemia." J Infect 25 (1992): 329-30

33. Gayet S, Ville E, Durand JM, Mars ME, Morange S, Kaplanski G, Gallais H, Soubeyrand J "Foscarnet-induced hypercalcaema in AIDS." AIDS 11 (1997): 1068-70

34. Barba R, GomezRodrigo J, Marco J, Espejo M, Mena D "Transient foscarnet-induced hypercalcaemia." AIDS 12 (1998): 1930-1

35. Holbrook J, Jabs D, Jacobson M, Mendez P, Min Y, Murphy R "Foscarnet-related abnormalities in serum creatinine, calcium, and magnesium in patients with CMV retinitis. The SOCA Research Group." Int Conf AIDS 9 (1993): 361

36. Guillaume MP, Karmali R, Bergmann P, Cogan E "Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS." Clin Infect Dis 25 (1997): 932-3

37. Fegeuex S, Salmon D, Picard C, et al "Penile ulcerations with foscarnet." Lancet 335 (1990): 547-8

38. Lacey HB, Ness A, Mandal BK "Vulval ulceration associated with foscarnet." Genitourin Med 68 (1992): 182

39. Gilquin J, Weiss L, Kazatchkine MD "Genital and oral erosions induced by foscarnet." Lancet 335 (1990): 287

40. Moyle G, Barton S, Gazzard BG "Penile ulceration with foscarnet therapy." AIDS 7 (1993): 140-1

41. Green ST, Nathwani D, Goldberg DJ, Mack DJ, Kennedy DH "Generalised cutaneous rash associated with foscarnet usage in AIDS." J Infect 21 (1990): 227-8

42. Caumes E, Gatineau M, Bricaire F, Dohin E, Katlama C, Gentilini M "Foscarnet-induced vulvar erosion." J Am Acad Dermatol 28 (1993): 799

43. Evans LM, Grossman ME "Foscarnet-induced penile ulcer." J Am Acad Dermatol 27 (1992): 124-6

44. Sohl Akerlund A, Keisu M, Lernestedt JO, Sandberg M "Penile ulcerations in connection with foscarnet therapy. Clinical picture and incidence." Int Conf AIDS 9 (1993): 358

45. Connolly GM, Gazzard BG, Hawkins DA "Fixed drug eruption due to foscarnet." Genitourin Med 66 (1990): 97-8

46. Brown DL, Sather S, Cheitlin MD "Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient." Am Heart J 125 (1993): 1439-41

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.